TapewireFind a company

person · Reporting owner

Boulding Mark Elliott

Disclosed activity across 1 company

Tapewire entity
21799
SEC CIK
0001578852

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
PTC THERAPEUTICS, INC.PTCT · Entity 3803EXEC. VP AND CLOOctober 09, 2026October 13, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

PTC THERAPEUTICS, INC.

Report date October 09, 2026 · Filed October 13, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect105,272 Ending reported balance After 2026-10-09 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2026-10-09 · Exercise / conversion · Acquired 192 · Balance 105,464

F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025.

Row 2 · 2026-10-09 · Sale · Disposed 192 · Balance 105,272

F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025.

F2: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.00 to $64.70 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.42 · Expires 2033-01-04Direct2,267 Reported balance After 2026-10-09 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-10-09 · Exercise / conversion · Disposed 192 · Balance 2,267

F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025.

F3: This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025.

F2: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.00 to $64.70 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F3: This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
March 11, 2025 Filed Mar 12, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 5,662 $53.02 $300,199.24
Disclosure

SEC source: 0001415889-25-007856 · form4-03122025_050301.xml · nonDerivative · entry 9

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 103,901

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 5, 2024.

F6 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $53.00 to $53.14 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
March 11, 2025 Filed Mar 12, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionCommon Stock 5,662 $33.02 $186,959.24
Disclosure

SEC source: 0001415889-25-007856 · form4-03122025_050301.xml · nonDerivative · entry 8

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 109,563

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 5, 2024.

Read SEC document
March 10, 2025 Filed Mar 12, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionStock Option (Right to Buy) · Derivative 11,249 $0.00 Strike: $25.69 $0.00
Disclosure

SEC source: 0001415889-25-007856 · form4-03122025_050301.xml · derivative · entry 14

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,751

Underlying: Common Stock · 11,249 shares

Expires 2034-02-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 5, 2024.

F9 · derivative.exercise_date: This option was granted on February 15, 2024, and vests over four years, with 25% of the shares underlying the option vesting on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025.

Read SEC document
March 10, 2025 Filed Mar 12, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionStock Option (Right to Buy) · Derivative 11,398 $0.00 Strike: $33.02 $0.00
Disclosure

SEC source: 0001415889-25-007856 · form4-03122025_050301.xml · derivative · entry 13

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,114

Underlying: Common Stock · 11,398 shares

Expires 2029-01-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 5, 2024.

F8 · derivative.exercise_date: Currently exercisable.

Read SEC document
March 10, 2025 Filed Mar 12, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionStock Option (Right to Buy) · Derivative 45,392 $0.00 Strike: $33.02 $0.00
Disclosure

SEC source: 0001415889-25-007856 · form4-03122025_050301.xml · derivative · entry 12

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,788

Underlying: Common Stock · 45,392 shares

Expires 2029-01-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 5, 2024.

F8 · derivative.exercise_date: Currently exercisable.

Read SEC document
March 10, 2025 Filed Mar 12, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 7,762 $53.05 $411,774.10
Disclosure

SEC source: 0001415889-25-007856 · form4-03122025_050301.xml · nonDerivative · entry 7

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 103,901

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 5, 2024.

F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $52.74 to $53.57 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
March 10, 2025 Filed Mar 12, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 3,487 $52.24 $182,160.88
Disclosure

SEC source: 0001415889-25-007856 · form4-03122025_050301.xml · nonDerivative · entry 6

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 111,663

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 5, 2024.

F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $51.73 to $52.71 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
March 10, 2025 Filed Mar 12, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionCommon Stock 11,249 $25.69 $288,986.81
Disclosure

SEC source: 0001415889-25-007856 · form4-03122025_050301.xml · nonDerivative · entry 5

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 115,150

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 5, 2024.

Read SEC document
March 10, 2025 Filed Mar 12, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 11,398 $53.12 $605,461.76
Disclosure

SEC source: 0001415889-25-007856 · form4-03122025_050301.xml · nonDerivative · entry 4

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 103,901

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 5, 2024.

F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $53.00 to $53.57 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
March 10, 2025 Filed Mar 12, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionCommon Stock 11,398 $33.02 $376,361.96
Disclosure

SEC source: 0001415889-25-007856 · form4-03122025_050301.xml · nonDerivative · entry 3

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 115,299

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 5, 2024.

Read SEC document
March 10, 2025 Filed Mar 12, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 45,392 $53.15 $2,412,584.80
Disclosure

SEC source: 0001415889-25-007856 · form4-03122025_050301.xml · nonDerivative · entry 2

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 103,901

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 5, 2024.

F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $53.00 to $53.82 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
March 10, 2025 Filed Mar 12, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionCommon Stock 45,392 $33.02 $1,498,843.84
Disclosure

SEC source: 0001415889-25-007856 · form4-03122025_050301.xml · nonDerivative · entry 1

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 149,293

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 5, 2024.

Read SEC document
February 20, 2025 Filed Feb 21, 2025 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 1,614 $50.12 $80,900.14
Disclosure

SEC source: 0001415889-25-005134 · form4-02212025_050204.xml · nonDerivative · entry 2

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 103,901

F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 4,500 RSUs from a February 15, 2024 grant of 18,000 RSUs and the vesting of 1,600 RSUs from a February 15, 2024 grant of 3,200 RSUs.

Read SEC document
February 19, 2025 Filed Feb 21, 2025 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 1,333 $50.10 $66,777.97
Disclosure

SEC source: 0001415889-25-005134 · form4-02212025_050204.xml · nonDerivative · entry 1

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 105,515

F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 4,500 RSUs from a February 15, 2024 grant of 18,000 RSUs and the vesting of 1,600 RSUs from a February 15, 2024 grant of 3,200 RSUs.

Read SEC document
January 08, 2025 Filed Jan 10, 2025 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 1,998 $44.50 $88,911.00
Disclosure

SEC source: 0001415889-25-001291 · form4-01102025_050103.xml · nonDerivative · entry 2

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 106,848

F2 · shares: Represents shares automatically sold pursuant to irrevocable sell to cover elections entered into upon acceptance of the respective grants to satisfy tax withholding obligations in connection with the vesting of 2,550 RSUs from a January 6, 2021 grant of 10,200 RSUs and the vesting of 3,600 RSUs from a January 7, 2022 grant of 14,400 RSUs.

Read SEC document
January 07, 2025 Filed Jan 10, 2025 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 1,543 $45.34 $69,959.62
Disclosure

SEC source: 0001415889-25-001291 · form4-01102025_050103.xml · nonDerivative · entry 1

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 108,846

F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 4,250 RSUs from a January 5, 2023 grant of 17,000 RSUs.

Read SEC document
January 03, 2025 Filed Jan 7, 2025 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 GrantStock Option (Right to Buy) · Derivative 45,000 $0.00 Strike: $46.54 $0.00
Disclosure

SEC source: 0001415889-25-001020 · form4-01072025_050111.xml · derivative · entry 2

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2035-01-02

F2 · derivative.exercise_date: This option was granted on January 3, 2025, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2026, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2026.

Read SEC document
January 03, 2025 Filed Jan 7, 2025 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 GrantCommon Stock 18,000 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-001020 · form4-01072025_050111.xml · nonDerivative · entry 1

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,389

F1 · shares: Restricted stock units granted on January 3, 2025 that vest in four equal installments over four years, commencing on January 3, 2026.

Read SEC document
December 03, 2024 Filed Dec 4, 2024 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionStock Option (Right to Buy) · Derivative 1,988 $0.00 Strike: $33.02 $0.00
Disclosure

SEC source: 0001415889-24-028285 · form4-12042024_051201.xml · derivative · entry 17

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,512

Underlying: Common Stock · 1,988 shares

Expires 2029-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on October 31, 2023.

F8 · derivative.exercise_date: Currently exercisable.

Read SEC document
December 03, 2024 Filed Dec 4, 2024 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionStock Option (Right to Buy) · Derivative 7,720 $0.00 Strike: $33.02 $0.00
Disclosure

SEC source: 0001415889-24-028285 · form4-12042024_051201.xml · derivative · entry 16

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 61,110

Underlying: Common Stock · 7,720 shares

Expires 2029-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on October 31, 2023.

F8 · derivative.exercise_date: Currently exercisable.

Read SEC document
December 03, 2024 Filed Dec 4, 2024 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionStock Option (Right to Buy) · Derivative 600 $0.00 Strike: $33.02 $0.00
Disclosure

SEC source: 0001415889-24-028285 · form4-12042024_051201.xml · derivative · entry 15

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,070

Underlying: Common Stock · 600 shares

Expires 2029-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on October 31, 2023.

F8 · derivative.exercise_date: Currently exercisable.

Read SEC document
December 03, 2024 Filed Dec 4, 2024 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 88 $54.14 $4,764.32
Disclosure

SEC source: 0001415889-24-028285 · form4-12042024_051201.xml · nonDerivative · entry 12

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 92,389

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on October 31, 2023.

Read SEC document
December 03, 2024 Filed Dec 4, 2024 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 1,900 $53.13 $100,947.00
Disclosure

SEC source: 0001415889-24-028285 · form4-12042024_051201.xml · nonDerivative · entry 11

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 92,477

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on October 31, 2023.

F7 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $53.00 to $53.62 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
December 03, 2024 Filed Dec 4, 2024 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionCommon Stock 1,988 $33.02 $65,643.76
Disclosure

SEC source: 0001415889-24-028285 · form4-12042024_051201.xml · nonDerivative · entry 10

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 94,377

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on October 31, 2023.

Read SEC document
December 03, 2024 Filed Dec 4, 2024 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 1,405 $54.05 $75,940.25
Disclosure

SEC source: 0001415889-24-028285 · form4-12042024_051201.xml · nonDerivative · entry 9

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 92,389

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on October 31, 2023.

F6 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $54.025 to $54.16 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
December 03, 2024 Filed Dec 4, 2024 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 6,315 $53.14 $335,579.10
Disclosure

SEC source: 0001415889-24-028285 · form4-12042024_051201.xml · nonDerivative · entry 8

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 93,794

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on October 31, 2023.

F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $53.00 to 53.995 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
December 03, 2024 Filed Dec 4, 2024 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionCommon Stock 7,720 $33.02 $254,914.40
Disclosure

SEC source: 0001415889-24-028285 · form4-12042024_051201.xml · nonDerivative · entry 7

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 100,109

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on October 31, 2023.

Read SEC document
December 03, 2024 Filed Dec 4, 2024 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 600 $53.04 $31,824.00
Disclosure

SEC source: 0001415889-24-028285 · form4-12042024_051201.xml · nonDerivative · entry 6

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 92,389

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on October 31, 2023.

F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $53.00 to $53.09 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
December 03, 2024 Filed Dec 4, 2024 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionCommon Stock 600 $33.02 $19,812.00
Disclosure

SEC source: 0001415889-24-028285 · form4-12042024_051201.xml · nonDerivative · entry 5

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 92,989

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on October 31, 2023.

Read SEC document
December 02, 2024 Filed Dec 4, 2024 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionStock Option (Right to Buy) · Derivative 83,640 $0.00 Strike: $51.00 $0.00
Disclosure

SEC source: 0001415889-24-028285 · form4-12042024_051201.xml · derivative · entry 14

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 83,640 shares

Expires 2025-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on October 31, 2023.

F8 · derivative.exercise_date: Currently exercisable.

Read SEC document
December 02, 2024 Filed Dec 4, 2024 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionStock Option (Right to Buy) · Derivative 1,960 $0.00 Strike: $51.00 $0.00
Disclosure

SEC source: 0001415889-24-028285 · form4-12042024_051201.xml · derivative · entry 13

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 83,640

Underlying: Common Stock · 1,960 shares

Expires 2025-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on October 31, 2023.

F8 · derivative.exercise_date: Currently exercisable.

Read SEC document
December 02, 2024 Filed Dec 4, 2024 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 83,640 $52.26 $4,371,026.40
Disclosure

SEC source: 0001415889-24-028285 · form4-12042024_051201.xml · nonDerivative · entry 4

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 92,389

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on October 31, 2023.

F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $52.00 to $52.91 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
December 02, 2024 Filed Dec 4, 2024 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionCommon Stock 83,640 $51.00 $4,265,640.00
Disclosure

SEC source: 0001415889-24-028285 · form4-12042024_051201.xml · nonDerivative · entry 3

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 176,029

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on October 31, 2023.

Read SEC document
December 02, 2024 Filed Dec 4, 2024 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 1,960 $52.17 $102,253.20
Disclosure

SEC source: 0001415889-24-028285 · form4-12042024_051201.xml · nonDerivative · entry 2

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 92,389

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on October 31, 2023.

F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $52.00 to $52.83 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
December 02, 2024 Filed Dec 4, 2024 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionCommon Stock 1,960 $51.00 $99,960.00
Disclosure

SEC source: 0001415889-24-028285 · form4-12042024_051201.xml · nonDerivative · entry 1

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 94,349

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on October 31, 2023.

Read SEC document
February 15, 2024 Filed Feb 16, 2024 21:10 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 GrantStock Option (Right to Buy) · Derivative 45,000 $0.00 Strike: $25.69 $0.00
Disclosure

SEC source: 0001415889-24-004104 · form4-02162024_040235.xml · derivative · entry 3

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2034-02-14

F3 · derivative.exercise_date: This option was granted on February 15, 2024, and vests over four years, with 25% of the shares underlying the option vesting on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025.

Read SEC document
February 15, 2024 Filed Feb 16, 2024 21:10 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 GrantCommon Stock 3,200 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-004104 · form4-02162024_040235.xml · nonDerivative · entry 2

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,389

F2 · shares: Restricted stock units granted on February 15, 2024 that vest in two equal installments over two years, commencing on February 15, 2025.

Read SEC document
February 15, 2024 Filed Feb 16, 2024 21:10 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 GrantCommon Stock 18,000 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-004104 · form4-02162024_040235.xml · nonDerivative · entry 1

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 89,189

F1 · shares: Restricted stock units granted on February 15, 2024 that vest in four equal installments over four years, commencing on February 15, 2025.

Read SEC document
January 30, 2024 Filed Feb 1, 2024 21:17 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 794 $27.25 $21,637.14
Disclosure

SEC source: 0001415889-24-002173 · form4-02012024_090230.xml · nonDerivative · entry 1

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 71,189

F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 2,550 RSUs from a January 29, 2020 grant of 10,200 RSUs.

Read SEC document
January 09, 2024 Filed Jan 10, 2024 21:04 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 1,938 $29.01 $56,230.68
Disclosure

SEC source: 0001415889-24-000910 · form4-01102024_090136.xml · nonDerivative · entry 2

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 71,983

F2 · shares: Represents shares automatically sold pursuant to irrevocable sell to cover elections entered into upon acceptance of the respective grants to satisfy tax withholding obligations in connection with the vesting of 2,550 RSUs from a January 6, 2021 grant of 10,200 RSUs and the vesting of 3,600 RSUs from a January 7, 2022 grant of 14,400 RSUs.

Read SEC document
January 08, 2024 Filed Jan 10, 2024 21:04 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 1,457 $28.64 $41,728.92
Disclosure

SEC source: 0001415889-24-000910 · form4-01102024_090136.xml · nonDerivative · entry 1

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 73,921

F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 4,250 RSUs from a January 5, 2023 grant of 17,000 RSUs.

Read SEC document
April 17, 2023 Filed Apr 19, 2023 20:09 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionStock Option (Right to Buy) · Derivative 58,631 $30.86 Strike: $30.86 $1,809,352.66
Disclosure

SEC source: 0001415889-23-006694 · form4-04192023_080455.xml · derivative · entry 6

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 58,631 shares

Expires 2026-01-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 2, 2022.

F4 · derivative.exercise_date: Currently exercisable.

Read SEC document
April 17, 2023 Filed Apr 19, 2023 20:09 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionStock Option (Right to Buy) · Derivative 3,292 $30.86 Strike: $30.86 $101,591.12
Disclosure

SEC source: 0001415889-23-006694 · form4-04192023_080455.xml · derivative · entry 5

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 58,631

Underlying: Common Stock · 3,292 shares

Expires 2026-01-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 2, 2022.

F4 · derivative.exercise_date: Currently exercisable.

Read SEC document
April 17, 2023 Filed Apr 19, 2023 20:09 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 58,631 $51.42 $3,014,553.91
Disclosure

SEC source: 0001415889-23-006694 · form4-04192023_080455.xml · nonDerivative · entry 4

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 75,378

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 2, 2022.

F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $51.00 to $51.825 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
April 17, 2023 Filed Apr 19, 2023 20:09 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionCommon Stock 58,631 $30.86 $1,809,352.66
Disclosure

SEC source: 0001415889-23-006694 · form4-04192023_080455.xml · nonDerivative · entry 3

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 134,009

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 2, 2022.

Read SEC document
April 17, 2023 Filed Apr 19, 2023 20:09 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 3,292 $51.42 $169,276.29
Disclosure

SEC source: 0001415889-23-006694 · form4-04192023_080455.xml · nonDerivative · entry 2

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 75,378

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 2, 2022.

F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $51.00 to $51.79 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
April 17, 2023 Filed Apr 19, 2023 20:09 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionCommon Stock 3,292 $30.86 $101,591.12
Disclosure

SEC source: 0001415889-23-006694 · form4-04192023_080455.xml · nonDerivative · entry 1

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 78,670

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 2, 2022.

Read SEC document
January 31, 2023 Filed Feb 2, 2023 21:18 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 812 $45.63 $37,049.94
Disclosure

SEC source: 0001415889-23-001794 · form4-02022023_090220.xml · nonDerivative · entry 1

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,378

F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 2,550 RSUs from a January 29, 2020 grant of 10,200 RSUs.

Read SEC document
January 11, 2023 Filed Jan 12, 2023 21:38 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 495 $44.36 $21,958.00
Disclosure

SEC source: 0001415889-23-000882 · form4-01122023_090135.xml · nonDerivative · entry 2

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,190

F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 3,600 RSUs from a January 7, 2022 grant of 14,400 RSUs.

Read SEC document
January 10, 2023 Filed Jan 12, 2023 21:38 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 590 $42.93 $25,330.41
Disclosure

SEC source: 0001415889-23-000882 · form4-01122023_090135.xml · nonDerivative · entry 1

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,685

F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 3,600 RSUs from a January 7, 2022 grant of 14,400 RSUs.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.